Article Text

Download PDFPDF

Original article
AMMECR1: a single point mutation causes developmental delay, midface hypoplasia and elliptocytosis
  1. Gaia Andreoletti1,
  2. Eleanor G Seaby1,
  3. Jennifer M Dewing2,
  4. Ita O'Kelly2,
  5. Katherine Lachlan1,3,
  6. Rodney D Gilbert4,
  7. Sarah Ennis1
  1. 1Human Genetics & Genomic Medicine, University of Southampton, Duthie Building (Mailpoint 808), Southampton General Hospital, Southampton, UK
  2. 2Centre for Human Development, Stem Cells and Regeneration HDH, University of Southampton, IDS Building, Southampton General Hospital, Southampton, UK
  3. 3Wessex Clinical Genetics Service, University Hospital Southampton NHS Foundation Trust, Princess Anne Hospital, Southampton, UK
  4. 4Wessex Regional Paediatric Nephro-Urology Service, Southampton Children's Hospital, Southampton, UK
  5. 5Faculty of Medicine, University of Southampton, Southampton, UK
  1. Correspondence to Dr Rodney D Gilbert, University Hospital Southampton NHS Foundation Trust Honorary Senior Lecturer, University of Southampton, Southampton SO16 6YD, UK; Rodney.Gilbert{at}uhs.nhs.uk

Abstract

Background Deletions in the Xq22.3–Xq23 region, inclusive of COL4A5, have been associated with a contiguous gene deletion syndrome characterised by Alport syndrome with intellectual disability (Mental retardation), Midface hypoplasia and Elliptocytosis (AMME). The extrarenal biological and clinical significance of neighbouring genes to the Alport locus has been largely speculative. We sought to discover a genetic cause for two half-brothers presenting with nephrocalcinosis, early speech and language delay and midface hypoplasia with submucous cleft palate and bifid uvula.

Methods Whole exome sequencing was undertaken on maternal half-siblings. In-house genomic analysis included extraction of all shared variants on the X chromosome in keeping with X-linked inheritance. Patient-specific mutants were transfected into three cell lines and microscopically visualised to assess the nuclear expression pattern of the mutant protein.

Results In the affected half-brothers, we identified a hemizygous novel non-synonymous variant of unknown significance in AMMECR1 (c.G530A; p.G177D), a gene residing in the AMME disease locus. Transfected cell lines with the p.G177D mutation showed aberrant nuclear localisation patterns when compared with the wild type. Blood films revealed the presence of elliptocytes in the older brother.

Conclusions Our study shows that a single missense mutation in AMMECR1 causes a phenotype of midface hypoplasia, mild intellectual disability and the presence of elliptocytes, previously reported as part of a contiguous gene deletion syndrome. Functional analysis confirms mutant-specific protein dysfunction. We conclude that AMMECR1 is a critical gene in the pathogenesis of AMME, causing midface hypoplasia and elliptocytosis and contributing to early speech and language delay, infantile hypotonia and hearing loss, and may play a role in dysmorphism, nephrocalcinosis and submucous cleft palate.

  • Clinical genetics
  • Complex traits
  • Diagnosis
  • Molecular genetics

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • GA, EGS, RDG and SE contributed equally.

  • Contributors GA: Exome analysis, co-wrote the first draft of the manuscript, and revised and approved final version. EGS: Exome analysis, collated phenotypic information, co-wrote the first draft, revised manuscript and approved the final version. JMD and IO'K performed transfection experiments, wrote the relevant part of the manuscript and approved the final version. KL: Clinical genetic input including phenotypic information. Revised manuscript and approved final version. RDG: Conceived project jointly with SE. Provided phenotypic data, revised manuscript and approved the final version. SE: Conceived project jointly with RDG. Supervised exomic analysis. Revised manuscript and approved the final version.

  • Funding This work was financially supported by the Biotechnology and Biological Sciences Research council (BBSRC), grant number BB/J008168/1. Miss Andreoletti is supported by The Crohn's in Childhood Research Association (CIRCA) and The Gerald Kerkut Charitable Trust.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional, unpublished data are included in this study.